The review discusses 58 peptides in different clinical phases, indicating a robust pipeline of peptide therapies targeting PPIs. Short protein and peptide therapeutics made by genetic code growth also have a brief 50 %-life due to their poor pharmacokinetics, such as fast serum degradation and brief elimination. Attaching a polymer https://englandf959rgx9.jasperwiki.com/user